In vivo pretargeting stands as a promising approach to harnessing the exquisite tumor-targeting
properties of antibodies for nuclear imaging and therapy while simultaneously skirting …

The overexpression of gastrin-releasing peptide receptor (GRPR) in cancer can be used for
peptide-receptor mediated radionuclide imaging and therapy. We have previously shown …

Patients with HER2-positive tumors often suffer resistance to therapy, warranting development
of novel treatment modalities. Affibody molecules are small affinity proteins which can be …

Affibody molecules are small (7 kDa), non-immunoglobulin scaffold proteins with a potential
as targeting agents for radionuclide imaging of cancer. However, high renal re-absorption of …

Affibody molecules are a class of small (∼7 kDa) robust scaffold proteins suitable for
radionuclide molecular imaging in vivo. The attachment of a hexahistidine (His 6 )-tag to the …

High expression of human epidermal growth factor receptor 2 (HER2) in breast and
gastroesophageal carcinomas is a predictive biomarker for treatment using HER2-targeted …

Engineered affibody molecules can be used for high contrast in vivo molecular imaging.
Extending a recombinantly produced HER2 binding affibody molecule with a hexa-histidine tag …

Affibody molecules are small proteins engineered using a nonantibody scaffold. Radiolabeled
Affibody molecules are excellent imaging probes, but their application to radionuclide …

Designed ankyrin repeat proteins (DARPins) are small engineered scaffold proteins that
can be selected for binding to desirable molecular targets. High affinity and small size of …

Gastrin‐releasing peptide receptors (GRPRs) are overexpressed in prostate cancer and are
suitable for targeted radionuclide therapy (TRT). We optimized the bombesin‐derived GRPR…